Clinical trials: Hepatitis C, completed
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Hepatitis C Virus
TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the…
- Trial name
- NCT01288742
- Testing
- Rosuvastatin, TMC435, Digoxin
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis c
Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy
Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity.Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related death in Egypt.It could be…
- Trial name
- NCT03612973
- Testing
- lipid profile, fasting insulin, fibro scan
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Hepatitis C Virus Infection
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants…
- Trial name
- NCT02994056
- Testing
- SOF/VEL, RBV
- Where
- 12 sites in United States, France
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Chronic Hepatitis C
Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response.
- Trial name
- DICO (NCT00909129)
- Testing
- pegylated interferon-alpha (Pegasys), ribavirin (COPEGUS)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Karolinska Institutet
HCV Infection
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA in adults with chronic Hepatitis C virus (HCV).
- Trial name
- NCT01072695
- Testing
- GS-9256, GS-9190, Ribavirin
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 46 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of blinded, single ascending oral doses of ABT 072 under non-fasting conditions in healthy adult Japanese male subjects.
- Trial name
- NCT01081483
- Testing
- ABT-072
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Abbott
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Acute, Diabetes
HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt
An observational double-blind cohort study that examined the association between HCV viral hepatitis, blood sugar level and systolic blood pressure in the Egyptian population
- Conditions
- Hepatitis C, Acute, Diabetes, Hypertension
- Trial name
- NCT03839979
- Testing
- BIOLINE HCV kits, ACCU-CHEK kits, ErKameter 3000 mercury manometer
- Where
- Egypt
- Volunteers
- 71,975 people, healthy volunteers welcome
- Sponsor
- Cairo University
Hepatitis C
Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C
This study is designed to compare the safety, tolerability and antiviral effects of omega interferon administered alone to omega interferon administered with ribavirin in the treatment of subjects with chronic Hepatitis C virus…
- Trial name
- NCT00097045
- Testing
- omega interferon, Ribavirin
- Where
- 3 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Intarcia Therapeutics
Alcoholism, Cirrhosis
Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound
The purpose of this study is to determine the amount of fibrosis in the liver of hepatitis C patients with advanced fibrosis, using endoscopic ultrasound.
- Conditions
- Alcoholism, Cirrhosis, Hepatitis c
- Trial name
- NCT01208311
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Chronic Hepatitis C Infection
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
Objectives: 1) To evaluate la proportion of hepatitic C virus (HCV)-monoinfected patients who show sustained virologic response (SVR) to treatment including direct-acting antivirals (DAAs) in the clinical practice in clinical…
- Trial name
- FPSMON201401 (NCT02333292)
- Testing
- Telaprevir, Boceprevir, Sofosbuvir
- Where
- Spain
- Volunteers
- 1,128 people
- Sponsor
- Valme University Hospital
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT01466192
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Tanabe Pharma Corporation
Liver Cirrhosis, Experimental
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
To evaluate: 1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study. 2.
- Trial name
- NCT00301509
- Testing
- peginterferon and ribavirin
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.
- Trial name
- NCT01508156
- Testing
- IDX719
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal hepatic function, moderate hepatic impairment…
- Trial name
- NCT02397707
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4
This study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants
- Trial name
- HCV (NCT04382339)
- Testing
- SOF/RBV/PegINFα-2
- Volunteers
- 99 people
- Sponsor
- Beni-Suef University
Cirrhosis, Chronic Hepatitis C
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Background: Some people who have chronic hepatitis C do not respond to the usual treatment with peginterferon and ribavirin. New chronic hepatitis treatments are being developed that may work better for different people.
- Conditions
- Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT01888900
- Testing
- DUAL, QUAD
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.